124 results about "Lectin" patented technology

Compositions containing a nucleic acid nanostructure having a desired geometric shape and an antigen and / or immunostimulatory agent(s) bound to its surface are provided. The nanostructure design allows for control of the relative position and / or stoichiometry of the immunostimulatory agent(s) bound to its surface. The antigen and / or immunostimulatory agent(s) displayed on the nanostructure surface are arranged with the preferred number, spacing, and 3D organization to elicit a robust immune response. The displayed antigen can be eOD-GT8. The immunostimulatory agent can be, e.g., T cell epitope such as a pan HLA DR-binding epitope (PADRE) and / or a lectin such as MBL or C3, or ligand thereof such as a glycan including mannose. Also provided are antigen-T cell epitope fusions such as eOD-PADRE and nanostructures presenting the same. The immunostimulatory compositions may thus be useful as immunogens, vaccines, adjuvants, and the like. Methods of inducing immune responses are also provided.

The present disclosure relates to methods of treating T-cell large granular lymphocytic leukemia (T-LGLL) with antibodies, or antigen-binding fragments thereof, that specifically bind to killer cell lectin-like receptor G1 (KLRG1), and methods for maintaining remission of T-cell large granular lymphocytic leukemia in a patient.

The invention provides an antrodia camphorata sporocarp extract, which is prepared from the following raw materials in parts by weight: 20 to 24 parts of wild ganoderma lucidum extract, 8 to 12 parts of herba taraxaci and 8 to 12 parts of bolete. The antrodia camphorata sporocarp extract disclosed by the invention contains various physiologically active components such as triterpenoids, polysaccharides, superoxide disproportionated enzymes, adenosine, proteins (containing immune proteins), vitamins, trace elements, nucleic acid, lectin, amino acid, sterols, lignin, blood pressure stabilizing substances and the like; the traditional Chinese medicine composition can relieve various tumors such as hangover, gastrointestinal discomfort, heatstroke, hypertension, virus infection, diabetes mellitus, nephritis, liver cirrhosis and liver cancer, has the effects of resisting oxidation, resisting inflammation, inhibiting hypertension, protecting liver nerves, inhibiting tumor growth and the like, can bidirectionally regulate immunity and protect the liver, can also treat tumors at multiple targets, and has a wide application prospect. The discomfort of a patient in an anti-tumor process is reduced.

The disclosure provides a chimeric antigen receptor (CAR) polypeptide having an antigen binding domain comprising an extracellular lectin which specifically binds to glycoproteins expressed on the surface of target cells. Also provided herein are engineered lymphocytes expressing the CAR polypeptide, a nucleic acid molecule encoding the CAR polypeptide, and methods of treating cancer.

The present application relates to the technical field of diagnostic markers, in particular to a marker combination and its application in diagnosing active tuberculosis and distinguishing between latent tuberculosis infection and active tuberculosis. The lectin combination provided by the present application can be used as a marker for ATB diagnosis and distinguishing between LTBI and ATB, and has high specificity and sensitivity. The lectin combination provided by the present application in combination with detection of specific antibodies of mycobacterium tuberculosis antigens can further improve the diagnostic effect. The marker and its detection products provided by the present application have good application potential in ATB diagnosis and distinguishing between LTBI and ATB, and are expected to overcome the limitations of existing diagnostic techniques, improve the diagnostic accuracy and sensitivity of tuberculosis, and provide new ideas and technical means for early detection, precise treatment and effective prevention and control of tuberculosis.

The invention belongs to the field of analysis and testing, and particularly relates to WGA-ConA double lectin modified magnetic nanoparticles for broad-spectrum separation of pathogenic bacteria as well as a preparation method and application of the WGA-ConA double lectin modified magnetic nanoparticles. The invention provides a WGA-ConA double lectin modified magnetic nanoparticle for broad-spectrum separation of pathogenic bacteria. The capture efficiency of the WGA-ConA double lectin modified magnetic nanoparticle on staphylococcus aureus, listeria monocytogenes, escherichia coli, pseudomonas aeruginosa and the like is greater than or equal to 85% under the condition that the pH is 6.5-7.5.

The invention relates to a ligand targeting neutrophil and neurons as well as a preparation method and application of the ligand. The ligand for targeting the neutrophil and the neuron is prepared from the following raw materials in parts by weight: 30 to 50 parts of DSPE-PEG-Tet1, 2 to 3 parts of ketal thiol with carboxyl groups at two ends and 30 to 50 parts of a neutrophil targeting ligand, the neutrophil targeting ligand is one or more of sialic acid, an anti-CD66b antibody, an anti-CD177 antibody, an anti-CD16b antibody, N-formylmethionine peptide (fMLF) and an analogue thereof, a CXCR1 / CXCR2 binding peptide, an integrin binding peptide, a selectin ligand and lectin. According to the invention, sequential targeting of neutrophile granulocytes-neurons can be realized, target cells of ischemic lesions can be accurately protected, and the improvement effect on the cerebral infarction area of MCAO rats can be obviously enhanced.

The invention relates to the technical field of aquatic animal immune regulation and control, in particular to rHoLL-like stepped lectin-like recombinant protein as well as a preparation method and application thereof. The recombinant protein has pathogen-related molecular pattern recognition and combination capabilities, can promote aggregation of pathogens in a body fluid environment, and activates an aquatic animal complement system, so that the non-specific immune defense capability is enhanced. The preparation method comprises the following steps: amplifying a HoLL-like mature peptide coding sequence, constructing a recombinant expression vector, and converting the recombinant expression vector into an escherichia coli expression host for induced expression to obtain rHoLL-like lectin-like recombinant protein existing in an inclusion body form; and carrying out affinity chromatography purification on the inclusion body protein, and carrying out renaturation treatment in a manner of gradient reduction of denaturant concentration to obtain the rHoLL-like stepped lectin-like recombinant protein. The rHoLL-like stepped lectin-like recombinant protein has good biological safety, and can be applied to aquaculture as an aquatic animal immunopotentiator or a related biological product.

The invention relates to a chemoenzymatic synthesis method of a high-glucose-type homogeneity mucoprotein core structural domain. The method comprises the following steps: firstly, catalytically synthesizing a key alpha-linked glycosylated amino acid block Fmoc-GalNacalpha-Ser / Thr-OH at a low temperature (-20 DEG C to 0 DEG C); then assembling the building blocks on a repeated polypeptide skeleton rich in proline, serine and threonine at accurate intervals (3-5 amino acid residues) through a solid-phase peptide synthesis technology to form a'sugar chain growth scaffold '; then, a series of high-specificity glycosyl transferases are used for carrying out sequential and directional sugar chain enzymatic extension on the scaffold, and a uniform core structure (such as a core type 3) is constructed; and finally, performing high-efficiency purification by a three-step series method of size exclusion chromatography, ion exchange chromatography and lectin affinity chromatography. The technical bottleneck of inhomogeneity (lt, 70%) of glycoforms in a traditional method is overcome, the mucoprotein core fragment with glycoform homogeneity larger than or equal to 95% and bioactivity highly similar to that of natural mucoprotein can be prepared on a large scale, and the method has wide application prospects in the biomedical fields of mucous membrane protective agents, drug delivery carriers and the like.

The present invention relates to a composition for preventing or treating lupus or glomerulonephritis comprising a recombinant stabilized Galectin-9 protein. Specifically, the recombinant stabilized Galectin-9 protein of the present invention has been confirmed to exhibit safety in a systemic lupus erythematosus (SLE) animal model, reduce skin lesions, lymphadenopathy, and proteinuria caused by lupus, ameliorate lupus nephritis and glomerulonephritis, and decrease the concentration of anti-dsDNA antibodies in plasma. Accordingly, the recombinant stabilized Galectin-9 protein of the present invention can be effectively used as an active ingredient in a composition for preventing or treating lupus or glomerulonephritis.

Compositions and methods of glycosylated virus-like particles (VLPs) displaying user-defined antigens and optionally encapsidating TLR ligands for targeting dendritic cell lectins have been developed. The VLPs employ ligands for a DC lectin e.g., DC-SIGN to activate dendritic cells (DC) and drive proliferation of antigen-specific CD8 and CD4-T cells specific for a user-defined antigen, such as a tumor antigens. In some forms, the compositions include aryl-mannose ligands to effectively generate DC-mediated TH-1 T cell responses to the user-defined antigen.

The application belongs to the technical field of molecular biology, and particularly relates to a long oyster C-type lectin CgCLec-TM2 functional domain CRD recombinant protein and application. The amino acid sequence of the long oyster C-type lectin CgCLec-TM2 functional domain CRD recombinant protein is shown as SEQ ID NO. 1. The rCRD obtained by the application has binding capacity to various pathogen-associated molecular patterns (PAMPs), can bind and agglutinate various microorganisms, has a growth inhibiting effect on gram-negative bacteria Vibrio splendidus and Escherichia coli, and can be used for the development of bacteriostatic feed additives and new-type immune enhancers.

The invention relates to the technical field of molecular biology and immunity, in particular to urechis unicinctus C-type lectin and a preparation method and application thereof. The amino acid sequence of the urechis unicinctus C-type lectin is as shown in SEQ ID No. 1. The C-type lectin is a recombinant protein obtained by expression in escherichia coli. The recombinant protein can be widely combined and agglutinated with various gram-positive bacteria and gram-negative bacteria, and can promote the removal of pathogenic bacteria in urechis unicinctus. The recombinant C-type lectin can be used for preparing a bacterial agglutination preparation, an anti-bacterial infection preparation and the like, and is especially suitable for prevention and control of aquaculture pathogenic bacteria.

Embodiments described herein relate to systems and methods for mapping molecules into interfaces. An example interface includes a visual interface having a map visualization. Example molecules include proteins, or any protein-like molecules or fragments thereof such as antibodies, antigens, proteins, lectins, receptors. Embodiments described herein relate to systems and methods for mapping molecules into interfaces by processing data using dimensionality reduction to generation representations of molecule maps (e.g. map visualizations).

The invention belongs to the technical field of molecular biology, and particularly relates to a method for detecting transgenic source soybeans in soybean oil through an LAMP-OSD probe. The invention provides a rapid, sensitive, specific and visual method which is used for detecting whether soybean oil contains transgenic soybean components or not and a small amount of fragmented DNA (deoxyribonucleic acid) in the soybean oil, and detecting the transgenic soybean components in the soybean oil by simultaneously or respectively detecting two most common transgenic selection marker elements, namely a CaMV 35S promoter and an NOS terminator and a soybean reference gene Lectin. And whether the transgenic soybean is used in the raw material of the soybean oil can be effectively identified.

The application belongs to the technical field of biological medicine, and particularly relates to a galactosamine-doxetaxel conjugate as well as a preparation method and application thereof. First, doxetaxel and 3,3'-diseleno-dipropionic acid are used as raw materials, and after heating reaction, 3,3'-diseleno-dipropionic acid doxetaxel is obtained. Then, the obtained 3,3'-diseleno-dipropionic acid doxetaxel and galactosamine are used as raw materials, and after heating reaction, galactosamine-3,3'-diseleno-dipropionic acid doxetaxel conjugate is obtained through column chromatography separation and purification. The obtained conjugate can be specifically recognized by endogenous lectin receptors (such as asialoglycoprotein receptor ASGPR) which are highly expressed on the surface of hepatoma cells, so as to be taken up by hepatoma cells through a receptor-mediated pathway, and has application prospect in the direction of hepatoma targeted treatment.

Provided herein are antibodies and antigen binding fragments thereof targeting the human C-type lectin-like molecule-1 (CLL-1) protein, as well as chimeric antigen receptors (CAR) derived from such antibodies and fragments, and the uses thereof.

The application discloses a kind of biological immobilized enzyme based on yeast surface display technology and the application of synthesis 2-phenylethanol, using yeast surface display technology, for the first time with Saccharomyces cerevisiae surface protein a-lectin as anchor protein, the key enzyme (transaminase, decarboxylase, ethanol dehydrogenase) involved in 2-PE producing Ehrlich pathway in Saccharomyces cerevisiae is separately or jointly carried out biological fixation, enhance substrate channel effect and proximity effect, in vitro one-step catalysis L-phenylalanine synthesis 2-PE, provide yield.The method for fixing multiple enzymes of Ehrlich pathway in the application can be used to reconfigure the biosynthesis pathway of other natural products in vitro, to provide feasible scheme for the rational design of cell factory.

The present invention provides an antibody or antigen-binding portion thereof that can bind to properdin (factor P). The antibody of the current invention leads to selective inhibition of alternative complement pathway while allowing the classical and lectin pathways to continue. Further, the antibody of the present invention may have modified or reduced binding to FcγRs to minimize its ADCC activity. The present invention provide an antibody that comprises an amino acid sequence to minimise its CDC activity. The antibody according to the present invention has higher FcRn binding affinity and therefore the antibody according to the present invention may have long circulating half-life in the body of the patient and it can be given at a reduced dosing frequency. The antibody according to the present invention can further be used in the preparation of a drug for treating diseases through inhibition of alternative complement pathway.

The invention belongs to the technical field of plant genetic engineering and crop breeding, and particularly relates to application of wheat lectin receptor-like kinase TaSIT2 and a coding gene TaSIT2 thereof in improving stripe rust resistance of crops. A wheat lectin receptor-like kinase gene TaSIT2 is analyzed and screened by using a reverse genetics method, a TaSIT2 gene editing wheat plant is obtained by using an agrobacterium-mediated genetic transformation method through a gene editing technology, the resistance of the transgenic plant to wheat stripe rust physiological races is remarkably enhanced, and the wheat stripe rust physiological races can be obtained. It is shown that knockout of the TaSIT2 gene enhances the resistance of wheat to stripe rust, it is determined that the wheat lectin receptor-like kinase TaSIT2 gene plays a negative regulation role in wheat stripe rust resistance, and a new technical thought and gene resources are provided for wheat stripe rust resistance variety cultivation from the perspective of molecular biology. And more paths are provided for cultivating lasting broad-spectrum disease-resistant varieties.

Provided herein are affinity matured anti-galectin-9 (Gal9) antibodies. The antibodies have improved binding affinity to Gal9. Also provided herein are method of use of the affinity matured anti-Gal9 antibodies, including methods of treatment of cancer, methods of rescuing or promoting effector T cell proliferation, methods of enhancing effector T cell activity, and / or of identifying and treating cancer in a subject including the administration of the anti-Gal9 antibodies described herein. Also provided are polynucleotides encoding the heavy chain or the light chain or the antigen-binding portion thereof described herein, and vectors, especially expression vectors, including the polynucleotides described herein.

This invention relates to the field of antibacterial technology. More specifically, it relates to a PEG-based polyvalent glycoside capable of dispersing mature biofilms, its preparation method, and its applications. The PEG-based polyvalent glycoside is a multi-arm polyethylene glycol with galactose grafted onto its terminal amino groups, as shown below, where n ranges from 10 to 60. This PEG-based polyvalent glycoside can specifically bind to bacterial lectins and has the ability to disperse mature biofilm structures. When used in combination with antibiotics, it can improve the sensitivity of bacteria within the biofilm to antibiotics.

A method of treating a target tissue area with a ribosome-inactivating protein. The method comprises injecting the target tissue area with an effective dose of a ribosome-inactivating protein and administering electroporation therapy to the target tissue area.

The present application belongs to the technical field of glycosylation detection and analysis, and particularly relates to a serum glycosylation flow analysis method based on lectin affinity. The present application enriches target molecules in a sample to be measured by coupling a polystyrene microsphere with a decoy molecule, and then incubates the polystyrene microsphere with a fluorescently labeled lectin, and directly analyzes the glycosylation information of the target molecules by a flow cytometer. In the present application, the decoy molecule of the target protein is coupled to the polystyrene microsphere to enrich the target protein, and the target protein is focused for subsequent analysis, which can effectively reduce the field of view and improve the specificity. After the lectin is combined with the target protein, the fluorescence analysis of the flow cytometry is directly performed, which can effectively reduce the damage of the washing operation to the affinity of the lectin, and thus overcomes the weakness of the weak affinity between the lectin and the sugar chain. Moreover, only a small amount of sample is required to realize the analysis of multiple lectins, and the washing-free real-time analysis can be realized, which provides a new way for the analysis of glycosylation by using lectin, and has important potential application value.

Provided herein are methods of analyzing post-translationally modified proteins. The methods may comprise pre-enriching proteins using lectins and / or multiplexed detection of multiple proteins and / or multiple post-translational modifications. Provided herein are also methods for determining the likelihood that a subject has a disease or condition, such as cancer.

It provides an inhibitor of complement activation. [Solution] An isolated monoclonal antibody and its antigen-binding fragment are provided that specifically bind to an epitope within the serine protease domain of human MASP-2. In some embodiments, the antibody or its antigen-binding fragment inhibits lectin pathway complement activation. Polynucleotides encoding the monoclonal antibody or its antigen-binding fragment, and cloning vectors or expression cassettes containing such polynucleotides are also provided. Methods for inhibiting lectin pathway complement activation and methods for treating diseases and disorders of the lectin pathway are further provided.

The invention provides a C-type lectin MnLec4 containing an LDLa structural domain as well as a coding gene and application thereof, and belongs to the technical field of gene engineering. The amino acid sequence of the C-type lectin MnLec4 containing the LDLa structural domain provided by the invention is as shown in SEQ ID NO. 1. The C-type lectin MnLec4 containing the LDLa structural domain, provided by the invention, can promote hemocyte to phagocytize aeromonas hydrophila, has a prevention and treatment effect on infection of aeromonas hydrophila, and can remarkably improve the survival rate of macrobrachium nipponensis infected by aeromonas hydrophila. After the C-type lectin MnLec4 is injected into the abdomen of the macrobrachium nipponense, the survival rate of the macrobrachium nipponense infected by the aeromonas hydrophila is remarkably increased, and the survival rate is 73.57% 96 hours after challenge.

This invention relates to the field of immunoassay technology, specifically to a multicolor fluorescent diagnostic reagent for detecting PAP. The multicolor fluorescent diagnostic reagent includes Hurst dye, wheat germ lectin, fluorescein isothiocyanate, a counterstaining agent, an organic solubilizer, and a humectant. This invention incorporates multiple fluorescent dyes, enabling rapid and effective detection of glycoprotein signals in PAP patient specimens. Simultaneously, it clearly displays cell morphology in the specimens, allowing for timely exclusion of bacteria, fungi, and abnormal cells, thus helping doctors quickly and accurately determine the type of PAP in patients. Compared to the traditional PAS staining method, the multicolor fluorescent diagnostic reagent provided by this invention uses a one-step staining method, which is simple to operate, has a short detection time, and allows for rapid observation of test results, facilitating timely diagnosis and treatment for patients.